Serum and urinary transforming growth factor beta 1 as biochemical markers in diabetic nephropathy patients

Shaker, Yehia; Soliman, Hanan A.; Ezzat, Elham; Hussein, Nervana S.; Ashour, Esmat; Donia, Ashraf; Eweida, Soad M.

doi:10.1016/j.bjbas.2014.02.002

Cited by 16 publications

(18 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been shown that elevated glycaemia activates inflammatory cells (neutrophils, macrophages, blood platelets) to TGF-β production. Excessive secretion and activity of TGF-β have been confirmed in diabetic nephropathy and retinopathy, and also in other pathological conditions [62]. However, in the present study, diabetes did not have a significant effect on TGF-β concentration, which was similar in both groups.…”

Section: Effects Of Continuous and Intermittent Exercise In Hypoxia Acontrasting

confidence: 47%

Effects of Hypoxia during Continuous and Intermittent Exercise on Glycaemic Control and Selected Markers of Vascular Function in Type 1 Diabetes

Hall

Żebrowska

Kamiński

et al. 2017

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

show abstract

Section: Effects Of Continuous and Intermittent Exercise In Hypoxia Acontrasting

confidence: 47%

Effects of Hypoxia during Continuous and Intermittent Exercise on Glycaemic Control and Selected Markers of Vascular Function in Type 1 Diabetes

Hall

Żebrowska

Kamiński

et al. 2017

Exp Clin Endocrinol Diabetes

View full text Add to dashboard Cite

show abstract

“…Serum TGF-β1 levels were found significantly higher in diabetic nephropathy patients (group III). These results are supported by Shaker et al [15]. Yaqiu et al and Shaker et al indicated that TGF-β1 levels increased in diabetic patients in accordance with various stages of albuminuria.…”

Section: Discussionsupporting

confidence: 64%

“…We also observed a positive and significant correlation of serum TGF-β1 level with HbA1c, fasting blood glucose and post prandial blood glucose. Shaker et al also reported a positive significant correlation between serum TGF-β1 and both glucose concentration and HbA1c [15]. Ibrahim et al have also found that serum TGF-β1 was significantly increased in patients with poor glycemic control with variable degree of renal dysfunction as compared to those with good glycemic control and comparable degree of renal dysfunction.…”

Section: Discussionmentioning

confidence: 90%

“…Yaqiu et al and Shaker et al indicated that TGF-β1 levels increased in diabetic patients in accordance with various stages of albuminuria. Therefore, the serum concentration of TGF-β1 levels increases in the early stages of diabetic nephropathy and keep elevating with the progression of DN [15,16]. Vishwanathan et al have also demonstrated significantly elevated TGF-β1 levels in South Indian type 2 diabetic patients when compared with the non-diabetic subjects.…”

Section: Discussionmentioning

confidence: 99%

“…However, TGF-β1 levels were not dependent on the duration of diabetes in the present study. There are some reports also indicating weak or no correlation of TGF-β1 with the duration of diabetes [15,16].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Study of serum transforming growth factor-beta 1 (TGF-?1) levels in type 2 diabetes mellitus patients with nephropathy

Shukla¹,

Kare²,

Banerjee³

et al. 2018

biomedicalresearch

View full text Add to dashboard Cite

Background: Diabetic nephropathy (DN) is a major micro-vascular complication of diabetes mellitus (DM) and it is the leading cause of end stage renal disease (ESRD) worldwide. The present study was carried out to estimate the serum TGF-β1 levels in T2DM patients with nephropathy. Methodology: All study subjects (n=75) were enrolled in 3 groups. Group 1: (n=25) healthy controls, group 2: (n=25) T2DM patients without nephropathy, group 3: (n=25) T2DM patients with nephropathy. Patients were recruited from diabetic and nephrology clinic at

show abstract

Novel biomarkers for prognosticating diabetic kidney disease progression

et al. 2022

View full text Add to dashboard Cite

The global burden of diabetic kidney disease (DKD) is escalating, and it remains as a predominant cause of the end-stage renal disease (ESRD). DKD is associated with increased cardiovascular disease and morbidity in all types of diabetes. Prediction of progression with albuminuria and eGFR is challenging in DKD, especially in non-proteinuric DKD patients. The pathogenesis of DKD is multifactorial characterized by injury to all components of the nephron, whereas albuminuria is an indicator of only glomerular injury. The limits in the diagnostic and prognostic value of urine albumin demonstrate the need for alternative and clinically significant early biomarkers, allowing more targeted and effective diabetic treatment, to reduce the burden of DKD and ESRD. Identification of biomarkers, based on multifactorial pathogenesis of DKD can be the crucial paradigm in the treatment algorithm of DKD patients. This review focuses on the potential biomarkers linked to DKD pathogenesis, particularly with the hope of broadening the diagnostic window to identify patients with different stages of DKD progression.

show abstract

Serum and urinary transforming growth factor beta 1 as biochemical markers in diabetic nephropathy patients

Cited by 16 publications

References 21 publications

Effects of Hypoxia during Continuous and Intermittent Exercise on Glycaemic Control and Selected Markers of Vascular Function in Type 1 Diabetes

Effects of Hypoxia during Continuous and Intermittent Exercise on Glycaemic Control and Selected Markers of Vascular Function in Type 1 Diabetes

Study of serum transforming growth factor-beta 1 (TGF-?1) levels in type 2 diabetes mellitus patients with nephropathy

Novel biomarkers for prognosticating diabetic kidney disease progression

Contact Info

Product

Resources

About